AstraZeneca PLC
AZNHealthcareNASDAQDrug Manufacturers - General
Headquartered within the healthcare sector, AstraZeneca PLC focuses on Drug Manufacturers - General services and products. AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. Valued at $261.12B, AZN is a mega-cap name in its sector. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI.
Market Cap
$261.12B
Beta
0.23
P/E (TTM)
24.76
P/E (Fwd)
18.17
EPS (TTM)
$6.80
EPS (Fwd)
$9.27
ROE
23.5%
ROA
8.5%
Cash
$7.67B
Total Debt
$34.03B
Free CF
$6.56B
52W Change
20.1%
Annual Financials
Cash vs Debt
The company holds $7.67B in cash, though total debt stands at $34.03B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Annual free cash flow of $6.56B supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 23.5%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 8.5% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $44.35B (2022) to $58.74B (2025), reflecting a 32% increase over the period.
The relatively low beta of 0.23 suggests AZN is a less volatile holding compared to the broader index. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing AZN.